Research-stage medication information

CagriSema Philadelphia: FDA Review and Investigational Status

Current CagriSema status in Philadelphia: submitted to FDA for weight management, not yet routinely prescribable, with approved alternatives.

Call 215-676-2334 Discuss approved options

CagriSema investigational medication information

Current status: Submission does not equal approval. As of September 1, 2026, CagriSema is not FDA approved and is not available for routine prescribing.

What is CagriSema?

CagriSema combines cagrilintide, an amylin analogue, with semaglutide. Novo Nordisk submitted it to the FDA for weight management in December 2025 based on pivotal studies.

Where is it in development?

FDA application under review. Clinical development and regulatory review can change. Trial results or an application submitted to FDA do not establish approval, broad safety, commercial availability or insurance coverage.

Review the cited sponsor or ClinicalTrials.gov status source.

Why W8MD does not routinely prescribe it

A medication that has not received FDA approval cannot be prescribed as an approved commercial treatment. W8MD does not sell or prescribe products labeled “for research use only,” nor does it treat an online chemical vendor as a substitute for an authorized clinical trial or regulated pharmacy.

Do not buy “research peptide” versions. Products sold through social media, overseas marketplaces, wellness sellers or chemical-supply websites may have uncertain identity, strength, sterility, storage and labeling. “Not for human consumption” is not a safety workaround. Do not inject or ingest such products.

Clinical trials are different from online sales

Authorized study

Uses a defined protocol, informed consent, eligibility criteria, oversight and systematic adverse-event monitoring.

Routine care

Uses legally available treatments after individual assessment and current prescribing information review.

Research-product sale

Does not become legitimate clinical care merely because a seller supplies a vial, certificate or dosing suggestion.

Approved options available now

Depending on eligibility, W8MD can discuss FDA-approved treatments such as Wegovy injection or tablets, Wegovy HD, Zepbound, Foundayo/orforglipron, Saxenda, Qsymia, Contrave or orlistat, as well as selected traditional prescriptions. The right option depends on medical conditions, interactions, preferences, coverage and cost.

Compare approved medications · GLP-1 clinic · Foundayo · Wegovy tablets · Costs

How W8MD can help

W8MD can explain the difference between promising research and currently available care, review whether a clinical trial is listed through legitimate channels, and help select an approved alternative while future evidence develops. W8MD does not guarantee trial eligibility or future approval.

Contact W8MD Philadelphia

1718 Welsh Road, 2nd Floor, Suite C, Philadelphia, PA 19115 · 215-676-2334

The first visit is in person. Call for appointments and questions about currently available treatments.

Request a non-urgent callback

Do not submit private medical, insurance or financial information.

For appointments and all other matters, call W8MD Philadelphia at 215-676-2334.

This form is only for non-urgent callback requests. Do not submit medical records, diagnoses, insurance numbers, financial information or other sensitive information.

First name

Last name

Phone number

Email address

Preferred W8MD office

Visit type

Service of interest

Non-confidential message (optional)

I understand that this form is for non-urgent callback requests only and agree not to submit private medical, insurance, financial or other sensitive information.

Security question
What is 6 plus 7?

Research and medical notice: Status checked September 1, 2026. Development programs, regulatory decisions and trial recruitment can change. This page is educational and is not medical advice, enrollment authorization or an offer to supply an investigational product.